Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19

According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Angelopoulou, Athina, Alexandris, Nikos, Konstantinou, Evangelia, Mesiakaris, Konstantinos, Zanidis, Charilaos, Farsalinos, Konstantinos, Poulas, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309930/
https://www.ncbi.nlm.nih.gov/pubmed/32846644
http://dx.doi.org/10.1016/j.envres.2020.109858
Descripción
Sumario:According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed.

Ejemplares similares